Rheumatoid Arthritis
Conditions
Interventions
Abatacept treatmentat month 12
MTX treatment at month 12
Sponsors
University of Occupational and Environmental Health, Japan
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.RA patients 2.Treated with MTX more than 6mg/week and biologic agents other than abatacept, DAS28-ESR less than 3.2 3.Patients with drug free wish 4.Consent about non-randomization 5.Patients who give a full consent to this study
Exclusion criteria
Exclusion criteria: 1,Contraindication with abatacept 2, Patients treated with abatacept 3, Using PSL, plasma pheresis, joint replacement and other surgical treatment 4 Chronic active EBV infection 5,Chronic HBV infection 6, Infection 7, Patients who are pregnant, who are nursing or who hope to be pregnant 8, Patients who are inadequate by investigator's decision.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with remission at month 24 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1, RF, anti CCP antibody at month 24 2, delta TSS at month 24 3. HAQ at month 24 4, DAS 28 at month 30 5, RF, anti CCP antibody at month 30 6, delta TSS at month 30 7, HAQ at month 30 | — |
Countries
Japan
Contacts
Public ContactShingo Nakayamada
University of Occupational and Environmental Health, Japan The First Department of Internal Medicine, School of Medicine
Outcome results
None listed